RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Aquestive Therapeutics Stock

Aquestive Therapeutics Employees 2024

Aquestive Therapeutics Employees

187

Ticker

AQST

ISIN

US03843E1047

WKN

A2JQ4G

In 2024, Aquestive Therapeutics employed 187 people, a 0% change from the 187 number of employees in the previous year.

Aquestive Therapeutics Aktienanalyse

What does Aquestive Therapeutics do?

Aquestive Therapeutics Inc is a biopharmaceutical company based in Warren, New Jersey. The company specializes in the development of drugs for neurological disorders, rare diseases, and other medical needs. It was founded in 2004 and went public in 2018. The company operates in two main business segments: the development of proprietary drugs and the development of film technology for drug delivery. Both segments are closely connected and aim to provide innovative solutions for urgent medical needs. Aquestive's first business segment is the development of proprietary drugs for neurological disorders such as epilepsy, Parkinson's disease, and migraines. The company has various drug candidates in the pipeline, including a film-based sublingual tablet for the treatment of epilepsy and an injection solution for Parkinson's. These drug candidates are designed to complement or improve existing treatment options and achieve higher efficacy and tolerability for patients. Aquestive's second business segment is the development of film technology for drug delivery. Aquestive's patented film technology enables fast and reliable drug administration and can help improve the treatment of many diseases. Aquestive's film technology is particularly designed for drug administration through the mucous membranes of the mouth and throat. This includes film formulations for sublingual, buccal, or oromucosal drug delivery. An example of an Aquestive product is the sublingual film formulation of diazepam, marketed under the trade name Sympazan. Sympazan is approved for the treatment of LGS (Lennox-Gastaut syndrome), a rare and severe form of epilepsy. The sublingual film formulation of diazepam provides rapid onset of action and increased tolerability for patients compared to traditional dosage forms such as tablets or capsules. Aquestive has also specialized in the development of generic drugs for mucous membrane administration. The company produces sublingual, buccal, and oromucosal film formulations for a variety of medications, including drugs for pain, allergies, and nausea. Aquestive's generic drugs offer higher efficacy and tolerability for patients compared to conventional dosage forms such as tablets or capsules. Overall, Aquestive is an innovative company dedicated to improving patients' lives through novel therapeutic approaches. The company specializes in the development of film technology for drug delivery, providing a variety of innovative solutions for urgent medical needs. With its proprietary drug candidates and expertise in film technology, Aquestive is well-positioned to continue offering groundbreaking solutions for medical care. Aquestive Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Aquestive Therapeutics's Employee Base

Aquestive Therapeutics's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Aquestive Therapeutics's operational capacity and future potential.

Year-to-Year Comparison

Assessing Aquestive Therapeutics's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Aquestive Therapeutics's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Aquestive Therapeutics’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Aquestive Therapeutics stock

How many employees does Aquestive Therapeutics have this year?

Aquestive Therapeutics has 187 undefined employees this year.

How many employees did Aquestive Therapeutics have compared to the previous year?

Compared to the previous year, Aquestive Therapeutics had 0% more employees.

What impact did the number of employees have on the company Aquestive Therapeutics?

The number of employees has a direct impact on the efficiency and productivity of Aquestive Therapeutics. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Aquestive Therapeutics?

The number of employees can also have an impact on investors of Aquestive Therapeutics, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Aquestive Therapeutics affect the company?

An increase in equity of Aquestive Therapeutics can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Aquestive Therapeutics's equity affect the company?

A reduction in equity of Aquestive Therapeutics can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Aquestive Therapeutics?

Some factors that can influence the equity of Aquestive Therapeutics include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Aquestive Therapeutics so important for investors?

The equity of Aquestive Therapeutics is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Aquestive Therapeutics influence the company?

The number of employees at Aquestive Therapeutics can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Aquestive Therapeutics evolved in recent years?

In recent years, the number of employees at Aquestive Therapeutics has changed by 0.

How many employees does Aquestive Therapeutics currently have?

Aquestive Therapeutics currently has 187 undefined employees.

Why is the number of employees important for investors of Aquestive Therapeutics?

The number of employees is important for investors of Aquestive Therapeutics as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Aquestive Therapeutics take to change the number of employees?

To change the number of employees, Aquestive Therapeutics can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Aquestive Therapeutics pay?

Over the past 12 months, Aquestive Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Aquestive Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Aquestive Therapeutics?

The current dividend yield of Aquestive Therapeutics is .

When does Aquestive Therapeutics pay dividends?

Aquestive Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Aquestive Therapeutics?

Aquestive Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Aquestive Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Aquestive Therapeutics located?

Aquestive Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Aquestive Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Aquestive Therapeutics from 10/27/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/27/2024.

When did Aquestive Therapeutics pay the last dividend?

The last dividend was paid out on 10/27/2024.

What was the dividend of Aquestive Therapeutics in the year 2023?

In the year 2023, Aquestive Therapeutics distributed 0 USD as dividends.

In which currency does Aquestive Therapeutics pay out the dividend?

The dividends of Aquestive Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Aquestive Therapeutics

Our stock analysis for Aquestive Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aquestive Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.